Secondary Logo

Journal Logo

Articles by Neeraj Narula

Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors

Dulai, Parambir S.; Battat, Robert; Barsky, Maria; More

The American Journal of Gastroenterology. 115(6):885-894, June 2020.

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Narula, Neeraj; Peerani, Farhad; Meserve, Joseph; More

The American Journal of Gastroenterology. 114(4):696, April 2019.

Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Narula, Neeraj; Peerani, Farhad; Meserve, Joseph; More

American Journal of Gastroenterology. 113(9):1345, September 2018.

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

Dulai, Parambir S; Singh, Siddharth; Jiang, Xiaoqian; More

American Journal of Gastroenterology. 111(8):1147-1155, August 2016.

Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium: 1904

Dulai, Parambir S.; Singh, Siddharth; Narula, Neeraj; More

American Journal of Gastroenterology. 110:S809, October 2015.